TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020

Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.

Kristin K Jørgensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.